For over 27 years OVP Venture Partners has led the drive into new, high-growth, complex-technology companies, with a concentration on the Pacific Northwest. We focus on early-stage investing in three core sectors – IT, Biotech and Cleantech. Our extensive experience includes over 53 successful exits – more than any other Pacific Northwest venture capital firm. OVP has over $750 million in capital under management and is currently investing its seventh fund. OVP has offices in Seattle and Portland.
The OVP team includes investing partners Chad Waite, Lucinda Stewart, Mark Ashida, Rick LeFaivre and Carl Weissman in Seattle and Gerry Langeler in Portland.
Monitor Ventures is an early-stage venture capital firm that partners with exceptional entrepreneurs to commercialize technology into world-class products and services. The Firm leverages the investment, operating and entrepreneurial experience of its partners to accelerate portfolio companies’ path to customers, capital and profitability.
We are committed to creating value by identifying strong entrepreneurs and building successful companies from the ground up. Our management team has more than 75 years combined investment, entrepreneurial and operating experience and has a demonstrated track record for identifying and investing in early-stage businesses.
BP Ventures identifies and invests in private, high growth, game-changing technology companies, accelerating cutting edge innovations across the entire energy spectrum. The Investment portfolio is primarily focused on emerging technologies in oil and gas exploration and production and downstream conversion processes. BP Ventures also partners with entrepreneurial companies specializing in biotech, water, advanced materials, and digital technology.
More information may be found at www.bp.com/ventures
DSM Venturing is an active investor in start-up companies, which create innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM Venturing’s mission is to explore emerging markets and technologies in order to support DSM’s innovation and growth strategy. Besides financial support, DSM Venturing supports the start-up companies with DSM’s knowledge, resources and networks in order to establish mutual benefits and learnings. To DSM, venturing is an integral part of DSM’s open innovation approach, focused on teaming up with innovative players all over the world. More information at: www.dsm.com.
DSM has annual net sales of about €9 billion and employs some 22,000 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. DSM is listed on Euronext Amsterdam. More information at: www.dsm-venturing.com.
Sime Darby is a Malaysia-based diversified multinational involved in key growth sectors, namely plantation, industrial equipment, motors, property and energy & utilities. It is supported by a workforce of more than 100,000 employees in over 20 countries and is one of the largest companies on Bursa Malaysia.
Capitalizing on being the world’s largest listed palm oil producer, Sime Darby established a Renewables unit in 2014 which spearheads the initiative to essentially focus on converting traditional and nontraditional palm-based commodities into products of higher value. The unit actively seeks investment opportunities in the bio-chemicals, nutraceuticals and bio-energy industry and envisions being a key player in the biobased technology space.
For more information on Sime Darby, please visit www.simedarby.com.
Verdezyne Sdn Bhd, together with Malaysian Bio-XCell Sdn Bhd and M+W Group have entered into a contract to build Verdezyne’s first bio-based commercial manufacturing facility. The facility will be located in the Malaysian Bio-XCell Biotechnology Park in Johor Bahru, Malaysia, and is designed to produce bio-based long chain diacids via fermentation of Verdezyne’s proprietary yeast. The first product to be produced at the plant will be dodecanedioic acid, a 12-carbon diacid which is a component of certain nylons, engineered plastics, corrosion inhibitors, pharmaceuticals and personal care items. This product will be made from non-food biobased raw materials such as spent biomass from palm oil processing. Construction commenced in February 2017 and commercial production is slated to begin in 2018.